Study of CT1190B for relapsed or refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma (like DLBCL, mantle cell, follicular, CLL/SLL, or PCNSL) that has come back or not responded after at least 2 prior treatments (or 1 for PCNSL).
- You need to be between 18 and 75 years old.
- You must have cancer that can be seen on a scan (CT, MRI, or PET) – a lymph node bigger than 1.5 cm, or a spot outside a node bigger than 1 cm, or a positive PET scan.
- Your overall health must be good enough (ECOG score 0-1, or 0-3 for PCNSL) and you should be expected to live more than 12 weeks.
- You cannot have had a previous treatment targeting CD19 (unless the CD19 or CD20 target is still found on your cancer cells).
- You must have acceptable organ function, including blood counts, kidney and liver function, and no serious heart or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.